{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:25:00Z","timestamp":1786991100729,"version":"build-2736575974"},"reference-count":85,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00c3\u00adfico e Tecnol\u00c3\u00b3gico","doi-asserted-by":"publisher","award":["302809\/2016-3"],"award-info":[{"award-number":["302809\/2016-3"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"Funda\u00c3\u00a7\u00c3\u00a3o de Amparo \u00c3\u00a0 Pesquisa do Estado de S\u00c3\u00a3o Paulo","doi-asserted-by":"publisher","award":["2016\/04000-3"],"award-info":[{"award-number":["2016\/04000-3"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Coordena\u00c3\u00a7\u00c3\u00a3o de Aperfei\u00c3\u00a7oamento de Pessoal de N\u00c3\u00advel Superior","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.intimp.2020.106296","type":"journal-article","created":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T04:30:16Z","timestamp":1581481816000},"page":"106296","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["Interleukin-2 as immunotherapeutic in the autoimmune diseases"],"prefix":"10.1016","volume":"81","author":[{"given":"Alexy","family":"Orozco Valencia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcos","family":"Camargo Knirsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emer","family":"Suavinho Ferro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Antonio Stephano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2020.106296_b0005","doi-asserted-by":"crossref","unstructured":"&NA, Aldesleukin, 2012. React Wkly. https:\/\/doi.org\/10.2165\/00128415-201214110-00012.","DOI":"10.2165\/00128415-201214110-00012"},{"key":"10.1016\/j.intimp.2020.106296_b0010","article-title":"High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update","author":"Atkins","year":"2000","journal-title":"Can. J. Sci. Am."},{"key":"10.1016\/j.intimp.2020.106296_b0015","unstructured":"J.-F. Bach, A. Perez-Arroyo, The Autoimmune Diseases, 2014."},{"key":"10.1016\/j.intimp.2020.106296_b0020","doi-asserted-by":"crossref","unstructured":"C. Baecher-Allan, B.J. Kaskow, H.L. Weiner, Multiple Sclerosis: Mechanisms and Immunotherapy. Neuron, 2018.","DOI":"10.1016\/j.neuron.2018.01.021"},{"key":"10.1016\/j.intimp.2020.106296_b0025","doi-asserted-by":"crossref","DOI":"10.1007\/s40264-014-0226-z","article-title":"Side effects of cytokines approved for therapy","author":"Baldo","year":"2014","journal-title":"Drug. Saf."},{"key":"10.1016\/j.intimp.2020.106296_b0030","doi-asserted-by":"crossref","DOI":"10.1093\/bioinformatics\/btq662","article-title":"Toward the estimation of the absolute quality of individual protein structure models","author":"Benkert","year":"2011","journal-title":"Bioinformatics"},{"key":"10.1016\/j.intimp.2020.106296_b0035","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-09654-8","article-title":"Modeling protein quaternary structure of homo- and hetero-oligomers beyond binary interactions by homology","author":"Bertoni","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.intimp.2020.106296_b0040","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkw1132","article-title":"The SWISS-MODEL Repository-new features and functionality","author":"Bienert","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.intimp.2020.106296_b0045","article-title":"Modulation of T cell responses by IL-2 and IL-2 complexes","author":"Boyman","year":"2015","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.intimp.2020.106296_b0050","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1126\/science.3500515","article-title":"Three-dimensional structure of interleukin-2","volume":") 238","author":"Brandhuber","year":"1987","journal-title":"Science (80-"},{"key":"10.1016\/j.intimp.2020.106296_b0055","doi-asserted-by":"crossref","DOI":"10.1007\/BF00874158","article-title":"Polyethylene glycol conjugated interleukin-2: Clinical and immunologic effects in patients with advanced renal cell carcinoma","author":"Bukowski","year":"1993","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.intimp.2020.106296_b0060","doi-asserted-by":"crossref","DOI":"10.1086\/515653","article-title":"Outpatient continuous intravenous interleukin-2 or subcutaneous, polyethylene glycol-modified interleukin-2 in human immunodeficiency virusinfected patients: a randomized, controlled, multicenter study","author":"Carr","year":"1998","journal-title":"J. Infect Dis."},{"key":"10.1016\/j.intimp.2020.106296_b0065","doi-asserted-by":"crossref","unstructured":"Ceccarelli F, Agmon-Levin N, Perricone C, 2017. Genetic Factors of Autoimmune Diseases 2017. J. Immunol. Res. 2017.","DOI":"10.1155\/2017\/2789242"},{"key":"10.1016\/j.intimp.2020.106296_b0070","doi-asserted-by":"crossref","unstructured":"P.H.N. Celie, A.H.A. Parret, A. Perrakis, Recombinant cloning strategies for protein expression, Curr. Opin. Struct. Biol., 2016.","DOI":"10.1016\/j.sbi.2016.06.010"},{"key":"10.1016\/j.intimp.2020.106296_b0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2018.06.006","article-title":"Pharmacodynamics of regulatory T cells in mice and humans treated with low-dose IL-2","author":"Churlaud","year":"2018","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.intimp.2020.106296_b0080","article-title":"Low-dose IL-2 therapy for autoimmune diseases","author":"Collison","year":"2019","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.intimp.2020.106296_b0085","doi-asserted-by":"crossref","unstructured":"C. Coppin, F. Porzsolt, M. Autenrieth, J. Kumpf, A. Coldman, T.J. Wilt, Immunotherapy for advanced renal cell cancer, Cochrane Database Syst. Rev. (2015).","DOI":"10.1002\/14651858.CD001425.pub3"},{"key":"10.1016\/j.intimp.2020.106296_b0090","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2005-12-4827","article-title":"Differential regulation of T-cell growth by IL-2 and IL-15","author":"Cornish","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2020.106296_b0095","doi-asserted-by":"crossref","unstructured":"J.C. Crisp\u00edn, G.C. Tsokos, Transcriptional regulation of IL-2 in health and autoimmunity. Autoimmun. Rev. (2009).","DOI":"10.1016\/j.autrev.2008.07.042"},{"key":"10.1016\/j.intimp.2020.106296_b0100","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/BF00417597","article-title":"Cloning and structure of a mouse interleukin-2 chromosomal gene","volume":"11","author":"Degrave","year":"1986","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.intimp.2020.106296_b0105","unstructured":"FDA, ONTAK \u00ae (denileukin diftitox) Solution for Intravenous use Initial U.S. Approval: 1999. @BULLET Warn Precautions 1, 2008."},{"key":"10.1016\/j.intimp.2020.106296_b0115","doi-asserted-by":"crossref","unstructured":"F.M. Foss, DAB389IL-2 (Denileukin Diftitox, ONTAK): A New Fusion Protein Technology. Clin Lymphoma, 2000. https:\/\/doi.org\/10.3816\/CLM.2000.s.005.","DOI":"10.3816\/CLM.2000.s.005"},{"key":"10.1016\/j.intimp.2020.106296_b0120","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.1995.13.3.688","article-title":"Results of treatment of 255 patients with metastatic renal cell carcinoma who received highdose recombinant interleukin-2 therapy","author":"Fyfe","year":"1995","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2020.106296_b0125","doi-asserted-by":"crossref","DOI":"10.1006\/cyto.2001.0862","article-title":"Signaling domains of the interleukin 2 receptor","author":"Gaffen","year":"2001","journal-title":"Cytokine"},{"key":"10.1016\/j.intimp.2020.106296_b0130","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1600-065X.1986.tb01492.x","article-title":"The human interleukin-2 receptor: analysis of structure and function","volume":"92","author":"Greene","year":"1986","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.intimp.2020.106296_b0135","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20100209","article-title":"IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells","author":"Grinberg-Bleyer","year":"2010","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.intimp.2020.106296_b0140","doi-asserted-by":"crossref","DOI":"10.1002\/elps.200900140","article-title":"Automated comparative protein structure modeling with SWISS-MODEL and Swiss-PdbViewer: a historical perspective","author":"Guex","year":"2009","journal-title":"Electrophoresis"},{"key":"10.1016\/j.intimp.2020.106296_b0145","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0083-6729(06)74007-9","article-title":"Interleukins and STAT Signaling","volume":"74","author":"Haque","year":"2006","journal-title":"Vitam. Horm."},{"key":"10.1016\/j.intimp.2020.106296_b0150","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S2213-8587(13)70113-X","article-title":"Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1\/2 randomised, double-blind, placebocontrolled trial","volume":"1","author":"Hartemann","year":"2013","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.intimp.2020.106296_b0155","doi-asserted-by":"crossref","DOI":"10.1016\/1380-2933(95)00009-7","article-title":"An IgG3-IL2 fusion protein activates complement, binds Fc\u03b3RI, generates LAK activity and shows enhanced binding to the high affinity IL-2R","author":"Harvill","year":"1995","journal-title":"Immunotechnology"},{"key":"10.1016\/j.intimp.2020.106296_b0160","doi-asserted-by":"crossref","DOI":"10.1093\/protein\/15.5.429","article-title":"Interleukin-2-collagen chimeric protein which liberates interleukin-2 upon collagenolysis","author":"Hayashi","year":"2002","journal-title":"Protein Eng."},{"key":"10.1016\/j.intimp.2020.106296_b0165","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1615\/CritRevImmunol.v18.i6.20","article-title":"The structure and function of gamma c-dependent cytokines and receptors: regulation of T lymphocyte development and homeostasis","volume":"18","author":"He","year":"1998","journal-title":"Crit. Rev. Immunol."},{"key":"10.1016\/j.intimp.2020.106296_b0170","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/ni.3077","article-title":"Control of PI(3) kinase in Tregcells maintains homeostasis and lineage stability","volume":"16","author":"Huynh","year":"2015","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.intimp.2020.106296_b0180","doi-asserted-by":"crossref","unstructured":"D. Klatzmann, A.K. Abbas, The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases. Nat. Rev. Immunol. (2015).","DOI":"10.1038\/nri3823"},{"key":"10.1016\/j.intimp.2020.106296_b0185","doi-asserted-by":"crossref","DOI":"10.1016\/S0005-2736(97)00269-1","article-title":"The development of IL-2 conjugated liposomes for therapeutic purposes","author":"Konigsberg","year":"1998","journal-title":"Biochim Biophys. Acta \u2013 Biomembr."},{"key":"10.1016\/j.intimp.2020.106296_b0190","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/300267a0","article-title":"A monoclonal antibody that appears to recognize the receptor for human T-cell growth factor; partial characterization of the receptor","volume":"300","author":"Leonard","year":"1982","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2020.106296_b0195","article-title":"THU0176 Efficiency and safety of rapamycin combined with low-dose IL-2 treatment compared with methotrexate in patients with rheumatoid arthritis","author":"Li","year":"2017","journal-title":"Wang C"},{"key":"10.1016\/j.intimp.2020.106296_b0200","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/ni.2030","article-title":"Modulation of cytokine receptors by IL-2 broadly regulates differentiation into helper T cell lineages","volume":"12","author":"Liao","year":"2011","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.intimp.2020.106296_b0205","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1182\/blood-2007-06-094615","article-title":"IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccinemediated T-cell immunity","volume":"110","author":"Litzinger","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2020.106296_b0210","doi-asserted-by":"crossref","first-page":"16311","DOI":"10.1016\/S0021-9258(17)46224-7","article-title":"IL2-PE66(4Glu), a new chimeric protein cytotoxic to human-activated T lymphocytes","volume":"265","author":"Lorberboum-Galski","year":"1990","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.intimp.2020.106296_b0215","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/nri.2016.93","article-title":"PI3K\u03b4 and primary immunodeficiencies","volume":"16","author":"Lucas","year":"2016","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.intimp.2020.106296_b0220","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1189\/jlb.0603272","article-title":"The main function of IL-2 is to promote the development of T regulatory cells","volume":"74","author":"Malek","year":"2003","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.intimp.2020.106296_b0225","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.immuni.2010.08.004","article-title":"Interleukin-2 receptor signaling: at the interface between tolerance and immunity","volume":"33","author":"Malek","year":"2010","journal-title":"Immunity"},{"key":"10.1016\/j.intimp.2020.106296_b0230","article-title":"Immunotherapy of metastatic renal cell carcinoma","author":"McDermott","year":"2008","journal-title":"Can. J."},{"key":"10.1016\/j.intimp.2020.106296_b0235","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/BF00172459","article-title":"Treatment of recurrent malignant glioma by repeated intracerebral injections of human recombinant interleukin-2 alone or in combination with systemic interferon-\u03b1. Results of a phase I clinical trial","volume":"12","author":"Merchant","year":"1992","journal-title":"J. Neurooncol."},{"key":"10.1016\/j.intimp.2020.106296_b0240","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.77.10.6134","article-title":"Purification and some characteristics of human T-cell growth factor from phytohemagglutinin-stimulated lymphocyte-conditioned media","author":"Mier","year":"1980","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.intimp.2020.106296_b0245","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0141864","article-title":"Functional modulation of regulatory T cells by IL-2","author":"Moon","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.intimp.2020.106296_b0250","doi-asserted-by":"crossref","unstructured":"Morgan DA, Ruscetti FW, Gallo R (1976) Selective in vitro growth of T lymphocytes from normal human bone marrows. Science (80-). https:\/\/doi.org\/10.1126\/science.181845.","DOI":"10.1126\/science.181845"},{"key":"10.1016\/j.intimp.2020.106296_b0255","doi-asserted-by":"crossref","unstructured":"A. Nicolini, P.A. Mancini, P. Ferrari, L. Anselmi, A. Sagripanti, A. Carpi, Immunological and side effects of low sc recombinant interleukin-2 dose in addition to conventional treatment in relapsed breast and colorectal cancer patients. In: Biomedicine and Pharmacotherapy, 1996.","DOI":"10.1016\/S0753-3322(96)89666-1"},{"key":"10.1016\/j.intimp.2020.106296_b0260","doi-asserted-by":"crossref","DOI":"10.1097\/01.NAJ.0000569452.97164.81","article-title":"The national library of medicine","author":"Ortelli","year":"2019","journal-title":"Am. J. Nurs."},{"key":"10.1016\/j.intimp.2020.106296_b0265","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1093\/intimm\/10.4.371","article-title":"Regulatory CD4 T cells: expression of IL-2R\u03b1 chain, resistance to clonal deletion and IL-2 dependency","volume":"10","author":"Papiernik","year":"1998","journal-title":"Int. Immunol."},{"key":"10.1016\/j.intimp.2020.106296_b0270","doi-asserted-by":"crossref","first-page":"6598","DOI":"10.4049\/jimmunol.177.10.6598","article-title":"Cutting edge: the phosphoinositide 3-kinase p110 Is critical for the function of CD4+CD25+Foxp3+ Regulatory T cells","volume":"177","author":"Patton","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2020.106296_b0275","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1084\/jem.178.4.1429","article-title":"Interleukin 2 activates extracellular signal regulated protein kinase 2","volume":"178","author":"Perkins","year":"1993","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.intimp.2020.106296_b0280","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0001581","article-title":"Negative feedback regulation of T cells via interleukin-2 and FOXP3 reciprocity","volume":"3","author":"Popmihajlov","year":"2008","journal-title":"PLoS ONE"},{"key":"10.1016\/j.intimp.2020.106296_b0285","doi-asserted-by":"crossref","DOI":"10.1186\/1479-5876-7-68","article-title":"Phase I\/II open-label study of the biologic effects of the interleukin-2 immunocytokine EMD 273063 (hu14.18-IL2) in patients with metastatic malignant melanoma","author":"Ribas","year":"2009","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.intimp.2020.106296_b0290","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1084\/jem.154.5.1455","article-title":"T cell growth factor receptors. Quantitation, specificity, and biological relevance","volume":"154","author":"Robb","year":"1981","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.intimp.2020.106296_b0295","doi-asserted-by":"crossref","unstructured":"Rose NR (2016) Autoimmune Diseases. In: International Encyclopedia of Public Health. pp 192\u2013195.","DOI":"10.1016\/B978-0-12-803678-5.00029-1"},{"key":"10.1016\/j.intimp.2020.106296_b0300","doi-asserted-by":"crossref","first-page":"5451","DOI":"10.4049\/jimmunol.1490019","article-title":"IL-2: the first effective immunotherapy for human cancer","volume":"192","author":"Rosenberg","year":"2014","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2020.106296_b0305","doi-asserted-by":"crossref","unstructured":"S.A. Rosenberg, J.C. Yang, D.E. White, S.M. Steinberg, Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: Identification of the antigens mediating response. In: Annals of Surgery, 1998. pp 307\u2013319.","DOI":"10.1097\/00000658-199809000-00004"},{"key":"10.1016\/j.intimp.2020.106296_b0310","doi-asserted-by":"crossref","DOI":"10.1146\/annurev-immunol-042617-053352","article-title":"Signaling and function of interleukin-2 in T lymphocytes","author":"Ross","year":"2018","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.intimp.2020.106296_b0315","first-page":"330","article-title":"Heterodimerization of the IL-2 receptor \u03b2- and \u03b3-chain cytoplasmic domains is required for signalling","volume":"369","author":"Russell","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2020.106296_b0320","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/0092-8674(93)80067-O","article-title":"Ulcerative colitis like disease in mice with a disrupted interleukin-2 gene","volume":"75","author":"Sadlack","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.intimp.2020.106296_b0325","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/j.0959-9673.2005.00436.x","article-title":"Effect of IL-2-Bax, a novel interleukin-2-receptor-targeted chimeric protein, on bleomycin lung injury","volume":"86","author":"Segel","year":"2005","journal-title":"Int. J. Exp. Pathol."},{"key":"10.1016\/j.intimp.2020.106296_b0330","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1084\/jem.20041982","article-title":"Homeostatic maintenance of natural Foxp3 + CD25 + CD4 + regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization","volume":"201","author":"Setoguchi","year":"2005","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.intimp.2020.106296_b0335","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1073\/pnas.94.7.3168","article-title":"Human immune disorder arising from mutation of the chain of the interleukin-2 receptor","volume":"94","author":"Sharfe","year":"2002","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.intimp.2020.106296_b0340","doi-asserted-by":"crossref","DOI":"10.2174\/138945007782151360","article-title":"Protein N-Glycosylation in the Baculovirus-Insect Cell System","author":"Shi","year":"2007","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.intimp.2020.106296_b0345","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/ni0705-639","article-title":"A history of immunology silverstein AM (2005) Paul Ehrlich, archives and the history of immunology","volume":"6","author":"Silverstein","year":"2009","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.intimp.2020.106296_b0350","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aan4931","article-title":"IL-2R abundance differentially tunes IL-2 signaling dynamics in CD4+and CD8+T cells","volume":"10","author":"Smith","year":"2017","journal-title":"Sci Signal"},{"key":"10.1016\/j.intimp.2020.106296_b0355","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1073\/pnas.0511161103","article-title":"Crystal structure of the IL-2 signaling complex: paradigm for a heterotrimeric cytokine receptor","volume":"103","author":"Stauber","year":"2006","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.intimp.2020.106296_b0360","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1096\/fasebj.5.2.1825981","article-title":"Functional diversity of T lymphocytes due to secretion of different cytokine patterns","volume":"5","author":"Street","year":"2018","journal-title":"FASEB J."},{"key":"10.1016\/j.intimp.2020.106296_b0365","doi-asserted-by":"crossref","unstructured":"H. Suzuki, T.M. K\u00fcndig, C. Furlonger, A. Wakeham, E. Timms, T. Matsuyama, R. Schmits, J.J.L. Simard, P.S. Ohashi, H. Griesser, T. Taniguchi, C.J. Paige, T.W. Mak, Deregulated T cell activation and autoimmunity in mice lacking interleukin-2 receptor \u03b2. Science (80-) 268 (1995) 1472\u20131476. https:\/\/doi.org\/10.1126\/science.7770771.","DOI":"10.1126\/science.7770771"},{"key":"10.1016\/j.intimp.2020.106296_b0370","article-title":"Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo controlled phase 2 trial","author":"Tepper","year":"2017","journal-title":"LancetNeurol"},{"key":"10.1016\/j.intimp.2020.106296_b0375","doi-asserted-by":"crossref","first-page":"5394","DOI":"10.1073\/pnas.84.15.5394","article-title":"The p75 peptide is the receptor for interleukin 2 expressed on large granular lymphocytes and is responsible for the interleukin 2 activation of these cells","volume":"84","author":"Tsudo","year":"1987","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.intimp.2020.106296_b0380","doi-asserted-by":"crossref","unstructured":"D. Vergani, G. Mieli-Vergani, C. The Autoimmune Diseases Von Spee-Mayer, E. Siegert, D. Abdirama, A. Rose, A. Klaus, T. Alexander, P. Enghard, B. Sawitzki, F. Hiepe, A. Radbruch, G.R. Burmester, G. Riemekasten, J.Y. Humrich, Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus Erythematosus. Ann Rheum Dis. (2016) https:\/\/doi.org\/10.1136\/annrheumdis-2015-207776.","DOI":"10.1136\/annrheumdis-2015-207776"},{"key":"10.1016\/j.intimp.2020.106296_b0385","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S0140-6736(13)60954-X","article-title":"Immunopathogenic mechanisms of systemic autoimmune disease","volume":"382","author":"Wahren-Herlenius","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.intimp.2020.106296_b0390","doi-asserted-by":"crossref","unstructured":"X. Wang, M. Rickert, K.C. Garcia, Structure of the quaternary complex of interleukin-2 with Its \u03b1, \u00df, and \u03b3<sub>c<\/sub> Receptors. Science (80-) 310 (2005) 1159 LP\u20131163.","DOI":"10.1126\/science.1117893"},{"key":"10.1016\/j.intimp.2020.106296_b0395","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gky427","article-title":"SWISS-MODEL: Homology modelling of protein structures and complexes","author":"Waterhouse","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.intimp.2020.106296_b0400","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.1301575","article-title":"Coupled IL-2\u2013dependent extracellular feedbacks govern two distinct consecutive phases of CD4 T cell activation","author":"Waysbort","year":"2013","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2020.106296_b0405","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/1074-7613(95)90180-9","article-title":"Interleukin-2 receptor \u03b1 chain regulates the size and content of the peripheral lymphoid compartment","volume":"3","author":"Willerford","year":"1995","journal-title":"Immunity"},{"key":"10.1016\/j.intimp.2020.106296_b0410","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/370153a0","article-title":"Involvement of the Jak-3 Janus kinase in signalling by interleukins 2 and 4 in lymphoid and myeloid cells","volume":"370","author":"Witthuhn","year":"1994","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2020.106296_b0415","first-page":"155","article-title":"Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, doseranging study","volume":"11","author":"Wolchok","year":"2010","journal-title":"LancetOncol"},{"key":"10.1016\/j.intimp.2020.106296_b0420","doi-asserted-by":"crossref","unstructured":"C. Ye, D. Brand, S.G. Zheng, Targeting IL-2: an unexpected effect in treating immunological diseases. Signal Transduct. Target. Ther. (2018).","DOI":"10.1038\/s41392-017-0002-5"},{"key":"10.1016\/j.intimp.2020.106296_b0425","doi-asserted-by":"crossref","DOI":"10.1016\/1043-4666(94)90016-7","article-title":"Positive and negative regulation of IL-2 gene expression: role of multiple regulatory sites","author":"Zhang","year":"1994","journal-title":"Cytokine"},{"key":"10.1016\/j.intimp.2020.106296_b0430","article-title":"In vivo targeting of adoptively transferred T-cells with antibody- and cytokine-conjugated liposomes","author":"Zheng","year":"2013","journal-title":"J. Control Release"},{"key":"10.1016\/j.intimp.2020.106296_b0435","doi-asserted-by":"crossref","unstructured":"J. Zitzmann, G. Sprick, T. Weidner, C. Schreiber, P. Czermak, Process optimization for recombinant protein expression in insect cells. In: New Insights into Cell Culture Technology, 2017.","DOI":"10.5772\/67849"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576919329443?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576919329443?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:14:59Z","timestamp":1761585299000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576919329443"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":85,"alternative-id":["S1567576919329443"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2020.106296","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interleukin-2 as immunotherapeutic in the autoimmune diseases","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2020.106296","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106296"}}